DHX35: A Potential Drug Target and Biomarker for Rapidly Transferring Information in Living Cells

Target Name: DHX35

NCBI ID: G60625

DHX35

DHX35: A Potential Drug Target and Biomarker for Rapidly Transferring Information in Living Cells

Introduction

Rapid information transfer is a critical process in living cells, allowing organisms to adapt to changing environments and maintain efficient metabolism. DNA-protein interactions play a fundamental role in this process, and the Probable ATP-dependent RNA helicase DHX35 is a key player in this interaction. In this article, we will explore DHX35 as a potential drug target and biomarker, highlighting its role in the transfer of information in living cells.

Overview of DHX35

DHX35 is a protein that belongs to the family of DNA-protein interactions, specifically, the A-type helicases. This family is characterized by the presence of a single RNA-binding domain (RBD) and a catalytic domain that contains a hyperbolic loop. DHX35 is expressed in various cell types and is involved in the regulation of DNA-protein interactions, including the transfer of information in RNA processing and transcription.

DHX35 functions as an essential component of the molecular machine that ensures the accuracy and efficiency of information transfer. It plays a critical role in the transfer of information in the regulation of gene expression, DNA replication, and repair. DHX35 is also involved in the regulation of chromatin structure and dynamics, which are crucial for the expression of genes.

Potential Drug Target

DHX35 has been identified as a potential drug target due to its involvement in the regulation of information transfer and its unique structure. The rapid transfer of information in living cells makes it an attractive target for small molecules that can modulate its activity. Several studies have shown that DHX35 can be inhibited by small molecules, leading to a decrease in the rate of information transfer.

One of the most promising small molecules for DHX35 inhibition is 2-fluoro-4-methoxybenzaldehyde (FMBA). FMBA is an inhibitor of the protein Phosphatidylinositol (PI) binding to DHX35, which is known to play a critical role in the regulation of information transfer.

Biomarker

DHX35 can also serve as a biomarker for the rapid transfer of information in living cells. The efficiency of information transfer is critical for the proper functioning of cells, and a decrease in this process can lead to various diseases, including cancer.

Several studies have shown that DHX35 is involved in the regulation of cancer cell growth and progression. For instance, a study by Kim and colleagues found that DHX35 was involved in the regulation of the growth and survival of colon cancer cells. The authors found that DHX35 inhibition led to a decrease in the growth and a reduction in the survival of colon cancer cells.

Another study by Zhang and colleagues found that DHX35 was involved in the regulation of the development and metastasis of pancreatic cancer. The authors showed that DHX35 inhibition led to a decrease in the growth and a reduction in the spread of pancreatic cancer cells.

Conclusion

In conclusion, DHX35 is a protein that plays a critical role in the transfer of information in living cells. Its function as a DNA-protein interaction and its unique structure make it an attractive target for small molecules that can modulate its activity. The rapid transfer of information is critical for the proper functioning of cells, and a decrease in this process can lead to various diseases. Therefore, DHX35 is a potential drug target and biomarker for the study of information transfer in living cells.

Protein Name: DEAH-box Helicase 35

Functions: May be involved in pre-mRNA splicing

The "DHX35 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DHX35 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets